trial · primary record
IMSA101
Metastatic Renal Cell Carcinoma ( mRCC)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2028-10 |
| Primary endpoint | To evaluate the PFS rate associated with the therapeutic intervention. PFS is defined as the duration of time from initiation of PULSAR/IMSA101 to disease progression as defined by RECIST1.1 or death. |
| Registry ID | NCT06601296 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:12.679Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06601296
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.